The listing application for the raw material drug Fluorouracil by Provon Pharmaceutical (000739.SZ) subsidiary has been approved.

Zhuhai Finance APP news, Pro Pharmaceuticals (000739.SZ) announced that its wholly-owned subsidiary Zhejiang Pro Jia Yuan Pharmaceutical Co., Ltd. has received the "Notice of Approval for the Registration Application of Chemical Raw Materials" for Fluorouracil from the National Medical Products Administration. This raw material is used to treat adult patients with advanced non-small cell lung cancer (NSCLC) who have the KRAS G12C mutation. This approval fully reflects the company's comprehensive competitiveness in areas such as CDMO business development, production, and system assurance, and will have a positive impact on the companys future operations. It will also strongly ensure the supply of Fluorouracil raw materials and assist partners in promoting product development.